Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA ephedrine proposal comment deadline extension urged by Reps. Boyd, Farr.

This article was originally published in The Tan Sheet

Executive Summary

FDA EPHEDRINE PROPOSAL COMMENT EXTENSION URGED BY REPS. BOYD, FARR in recent letters to the agency. Allen Boyd (D-Fla.) and Sam Farr (D-Calif.) support the allowance of additional time to facilitate public input to the proposed rule, which would establish serving limits and label warnings for dietary supplements containing ephedrine alkaloids ("The Tan Sheet" June 9, pp. 20-23). Rep. Boyd, a member of the House Small Business Committee, states in a Nov. 12 letter that "the management of this rule has made it difficult, if not impossible, for small businesses to participate in the rulemaking process."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel